Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aaron Farrow

Neurology Oklahoma City, OK Medical Doctor

NPI 1376864439 CMS profile 335018

711 Stanton L Young Blvd, Oklahoma City, OK 73104

Open in the dashboard

General payments

$172,161

2,120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Farrow of Oklahoma City, OK is reported in the CMS Open Payments database as having received $172,161 across 2,120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,624 306
2024 General $29,031 313
2023 General $15,216 322
2022 General $24,406 382
2021 General $17,473 307
2020 General $15,667 216
2019 General $23,745 274

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Farrow
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Aaron Farrow were reported at $46,624. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Aaron Farrow Neurology median Middle half National median
2019 $23,745 $474 $118–$2,177 $163
2020 $15,667 $367 $82–$2,309 $114
2021 $17,473 $438 $104–$2,547 $132
2022 $24,406 $442 $103–$2,388 $149
2023 $15,216 $464 $119–$2,312 $160
2024 $29,031 $468 $119–$2,323 $164
2025 $46,624 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $116,566 183 payments
  2. AbbVie, Inc. $30,546 317 payments
  3. UCB, Inc. $1,966 111 payments
  4. Novartis Pharmaceuticals Corporation $1,551 135 payments
  5. Teva Pharmaceuticals USA, Inc. $1,322 129 payments
  6. Lundbeck LLC $1,222 68 payments
  7. Allergan Inc. $1,033 83 payments
  8. Amgen Inc. $1,030 66 payments
  9. ACADIA Pharmaceuticals Inc $968 67 payments
  10. Alexion Pharmaceuticals, Inc. $916 46 payments
  11. Other $15,040 915 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $119,869 50 payments
  2. Food and Beverage $31,469 2,025 payments
  3. Consulting Fee $17,440 15 payments
  4. Travel and Lodging $3,234 23 payments
  5. Education $149 7 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $43,770 95 payments
  2. VUMERITY Neurology $32,772 56 payments
  3. VUMERITY Neurology $24,164 33 payments
  4. QULIPTA $22,569 174 payments
  5. UBRELVY $18,733 122 payments
  6. TECFIDERA $13,172 35 payments
  7. AVONEX $2,292 16 payments
  8. PLEGRIDY $2,185 4 payments
  9. AIMOVIG $1,064 69 payments
  10. BOTOX $922 70 payments
  11. Other $25,208 1,688 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

3,979

Median for Neurology: 833

Drug cost

$1,949,818

Median for Neurology: $202,670

Branded share of claims

30.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex Pen (4 Pack) Interferon Beta-1a Brand 27 $288,962
Ingrezza Valbenazine Tosylate Brand 22 $178,139
Nurtec Odt Rimegepant Sulfate Brand 67 $131,814
Kesimpta Pen Ofatumumab Brand 13 $131,046
Ubrelvy Ubrogepant Brand 78 $121,215
Xcopri Cenobamate Brand 94 $114,616
Vumerity Diroximel Fumarate Brand 13 $113,508
Nuplazid Pimavanserin Tartrate Brand 13 $110,614
Aubagio Teriflunomide Brand 12 $109,668
Teriflunomide Generic 81 $89,411

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$232,299

Of which drugs: $156,938

Medicare patients

458

Average age 73

Services billed

32,434

274 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Depression 34%
Ischemic heart disease 33%
Chronic kidney disease 31%
Diabetes 27%
Atrial fibrillation 22%
Alzheimer's or dementia 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 43 31,600 $156,938

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VUMERITY
$12,938 13 —
QULIPTA
$6,684 — —
TYSABRI
$5,025 — —
VYEPTI
$296 — —
BOTOX
$271 16 31,600

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

2,120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record